#Japan #Tokyo #AMDAP #Physiologas #Hemodialysis Device

Physiologas Technologies' Breakthrough in Home Hemodialysis

Physiologas Technologies, headquartered in Kanagawa, Japan, has recently been chosen as a recipient of support under Tokyo's Advanced Medical Device Acceleration Project (AMDAP). This initiative promotes the development of advanced medical devices by small and medium-sized enterprises, providing significant funding potential of up to 600 million yen over six years. The company's focus is on creating a home hemodialysis device that eliminates the need for water supply systems, greatly easing the burden on patients.

Understanding the Need for Home Hemodialysis

Currently, in-clinic hemodialysis is the standard treatment for approximately 340,000 end-stage kidney failure patients in Japan, involving lengthy sessions that can take up valuable time and cause significant physical strain. The existing home hemodialysis devices require complex water supply and drainage systems, making them large and difficult to operate without medical training. This results in a very low adoption rate for home treatment, with only about 800 patients opting for such a solution in Japan.

Physiologas aims to address these challenges by developing a compact, user-friendly home hemodialysis system featuring a unique technology that recirculates dialysis fluid within the machine. This innovation allows patients to perform treatments easily at home, enhancing their quality of life and potentially improving clinical outcomes.

The AMDAP Initiative and Its Importance

The AMDAP program supports the ambitious goals of Tokyo's commitment to medical device innovation. The initiative recognizes that while Japan has strong capabilities in diagnostic equipment, there is a significant opportunity for growth in therapeutic devices, where imported products currently dominate the market. By concentrating expertise and resources within Tokyo, the AMDAP seeks to bolster domestic production of reliable medical devices.

Through the program, Physiologas will receive specialized guidance from experts in various fields, focusing on transforming innovative business plans into viable products that can advance healthcare practices. This support is critical for the development of small, highly effective hemodialysis devices that can provide patients with practical and life-changing solutions.

A Promising Future with Physiologas' Device

Physiologas is at the forefront of developing technology that can significantly impact the lives of patients with end-stage kidney disease. The company's approach is rooted in the research of Dr. Kenichi Kokubo from Kitasato University, who has contributed to the creation of a system capable of detoxifying waste products, allowing for the recirculation of dialysis fluid. This functionality not only makes treatment easier but also improves safety.

With the introduction of this home hemodialysis system, patients can expect a significant increase in their quality of life. Not only does it help in reducing the physical and emotional toll of regular hospital visits, but it also enhances prospects for social reintegration and employment among patients, showcasing the economic benefits of this innovation.

Physiologas Technologies: Innovating Healthcare

Founded in March 2020, Physiologas Technologies is a startup derived from Kitasato University, driven by the mission to innovate healthcare through technology. Their core belief is in delivering happier lives for patients and their families through novel medical solutions. With a capital of 307 million yen (as of December 31, 2025), the company is uniquely positioned to make meaningful contributions to the healthcare system.

As the development of this device progresses, Physiologas looks forward to setting a new standard for home hemodialysis treatment, ultimately leading the way for other innovative healthcare solutions in the near future.

For more information, please visit Physiologas Technologies.